Originalarbeiten

Weide R, Feiten S, Waßmann C, Rendenbach B, Braun U, Burkhard O, Ehscheidt P, Schmidt M.
Metastatic Breast Cancer: Prolonging Life in Routine Oncology Care.
Cancers 2024, 16, 1255. https://www.mdpi.com/2072-6694/16/7/1255

Chakupurakal G, Feiten S, Schnell R, Steinmetz TH, Müller L, Burkhard O, Braun U, Ehscheidt P, Tamm I, Rendenbach B, Weide R.
Age and Performance Status Significantly Influence Outcome despite the Advent of New Therapy Options in Multiple Myeloma.
Cancer Sci Res. 2024; 7(2): 1-6. https://www.scivisionpub.com/journals/articleinpress-cancer-science-research

Lutz C, Feiten S, Chakupurakal G, Heymanns J, Thomalla J, van Roye C, Weide R.
Patients with indolent lymphomas are at high risk of infections: experience from a German outpatient clinic.
BMC Immunol 24, 2 (2023). https://doi.org/10.1186/s12865-022-00536-x

Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, Hänel M, Mann C, Asemissen AM, Heilmeier B, Weinhold N, Huhn S, Kriegsmann K, Luntz SP, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Khandanpour C, Knauf W, Scheid C, Munder M, Geer T, Riesenberg H, Thomalla J, Hoffmann M, Raab MS, Salwender HJ, Weisel KC, for the German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators.
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
The Lancet Haematology 2022, 9(11):e810-e821.

Weide R, Thomalla J, van Roye C, Chakupurakal G, Heymanns J, Köppler H, Feiten S, Nickel JA, Schmidberger H, Theobald M, Lutz C.
Curricular course for medical students at a hematology and oncology specialty practice, 2010-2022.
GMS J Med Educ. 2022;39(4):Doc40. DOI: 10.3205/zma001561, URN: urn:nbn:de:0183-zma0015619

Geßner C, Fietz T, Losem C, Lück A, Schulz H, Niemeier B, Groschek M, Eschenburg H, Weide R, Kretzschmar A, Frost N, Hipp J, Harde J, Matillon CD, Grebhardt S, Potthoff K.
Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with lung cancer: final results from the non-interventional study NADIR.
Current Medical Research and Opinion, DOI: 10.1080/03007995.2022.2113693

Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer J-U, Furlanetto J, Zahm D-M, Hanusch C, Thomalla J, Jackisch C, Staib P, Link T, Rhiem K, Solbach C, Fasching P A, Nekljudova V, Denkert C, Untch M, GBG and AGO-B.
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.
Ann Oncol (2022); S0923-7534(22)03791-7. doi: 10.1016/j.annonc.2022.07.1940

Laakmann E, Witzel I, Neunhöffer T, Park-Simon T-W, Weide R, Riecke K, Polasik A, Schmidt M, Puppe J, Mundhenke C, Lübbe K, Hesse T, Thill N, Zahm D-M, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Müller V.
Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry.
ESMO Open (2022); 7(3):100495. doi: 10.1016/j.esmoop.2022.100495

Feiten S, Scholl I, Dünnebacke J, Schmidt M, Franzen A, Ernst W, Spaderna H, Weide R.
Shared decision-making in routine breast cancer care in Germany—A cross-sectional study.
Psychooncology (2022); 1‐7. https://doi.org/10.1002/pon.5898

Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry-Comparison of Three Different GPA Prognostic Scores.
Cancers (2021); 17;13(4): 844. doi:10.3390/cancers13040844.

Massa C, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer JU, Zahm DM, Jackisch C, van Mackelenbergh M, Thomalla J, Marme F, Huober J, Müller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching PA, Untch M, Loibl S, Weber K, Seliger B.
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC.
J Immunother Cancer (2020); 8(2): e001261. doi:10.1136/jitc-2020-001261.

Laakmann E, Witzel I, Neunhöffer T, Weide R, Schmidt M, Park-Simon TW, Möbus V, Mundhenke C, Polasik A, Lübbe K, Hesse T, Riecke K, Thill M, Fasching PA, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Müller V.
Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases.
Cancers (2020); 12(10): 2787. doi:10.3390/cancers12102787.

Weide R , Schnell R, Schardt C, Koenigsmann M, Otremba B, Zahn M-O, Wierecky J, Braun U, Hensel M, Klausmann M, Fleckenstein D, Ehscheidt P, Feiten S.
Health status and infections in patients with symptomatic primary and secondary immunoglobulin G (IgG) deficiencies receiving intravenous IgG replacement.
BMC Immun (2020) 21:39. https://doi.org/10.1186/s12865-020-00368-7

Kutsch N, Bahlo J, Robrecht S, Franklin J, Zhang C, Maurer C, De Silva N, Lange E, Weide R, Kiehl MG, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Herling M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Böttcher S, Stilgenbauer S, Fink AM, Hallek M, Eichhorst B.
Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG).
Hemasphere (2020); 4(1): e336. doi:10.1097/HS9.0000000000000336.

Rosentreter J, Alt J, Fried M, Chakupurakal G, Stratmann J, Krämer I.
Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors.
J Oncol Pharm Pract (2020). doi: 10.1177/1078155220946381.

Kowalski C, Albert U-S, Baumann W, Carl G, Ernstmann N, Hermes-Moll K, Fallenberg E A, Feick G, Feiten S, Härter M, Heidt V, Heuser C, Hübner J, Joos S, Katalinic A, Kempkens Ö, Kerek-Bodden H, Klinkhammer-Schalke M, Koller M, Langer T, Lehner B, Lux M P, Maatouk I, Pfaff H, Ratsch B, Schach S, Scholl I, Skoetz N, Voltz R, Wiskemann J, Inwald E C.
DNVF Memorandum Versorgungsforschung in der Onkologie.
Das Gesundheitswesen (2020). doi: 10.1055/a-1191-3759.

Weide R.
Infektionskontrolle bei hämatologischen und onkologischen Neoplasien.
TumorDiagn u Ther (2020); 41: 299-301. https://doi.org/10.1055/a-1132-1156.

Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995-2017.
Leuk Lymphoma (2019); 61(3): 557-566. https://doi.org/10.1080/10428194.2019.1680840.

Feiten S, Chakupurakal G, Feustel HP, Maasberg M, Otremba B, Ehscheidt P, Hensel M, Hansen R, Weide R.
Response to the letter to the Editor concerning our article ‚High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany‘
Support Care Cancer (2019). https://doi.org/10.1007/s00520-019-05126-z

Chakupurakal G, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Köppler H, Lutschkin J, Thomalla J, van Roye C, Weide R.
Treatment and Outcome of Patients with Palliative Non-small Cell Lung Cancer (NSCLC) in Routine Outpatient Care Over Two Decades.
J Cancer Sci Ther/Vol.11.5 167(2019), Vol 11(5)

Vitinius F, Rarek M, Peltzer S, Heymanns J.
Entfernungen überbrücken – Telemedizin. In: Jünger J. (Hrsg.) 2018. Ärztliche Kommunikation: Praxisbuch zum Masterplan Medizinstudium 2020, Stuttgart: Schattauer, S. 570 – 575.

Feiten S, Chakupurakal G, Feustel HP, Maasberg M, Otremba B, Ehscheidt P, Hensel M, Hansen R, Weide R.
High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany. Support Care Cancer (2019), 27:4265–4271. doi: 10.1007/s00520-019-04721-4

Schneeweiss A, Möbus V, Tesch H, Hanusch C, Denkert C, Lübbe K, Huober J, Klare P, Kümmel S, Untch M, Kast K, Jackisch C, Thomalla J, Ingold-Heppner B, Blohmer JU, Rezai M, Frank M, Engels K, Rhiem K, Fasching PA, Nekljudova V, von Minckwitz G, Loibl S.
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. Eur J Cancer. 2019;106:181-192.

Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, Krause SW, Kolb HJ, Hossfeld DK, Nerl C, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Balleisen L, Goebeler ME, Hänel M, Ho A, Dengler J, Falge C, Möhle R, Kremers S, Kneba M, Stegelmann F, Köhne CH, Lindemann HW, Waller CF, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Schenk M, Brossart P, Wündisch T, Geer T, Bildat S, Schäfer E, Hasford J, Hehlmann R, Pfirrmann M.
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV. Haematologica. 2018 Dec 4. pii: haematol.2018.206797. doi: 10.3324/haematol.2018.206797. [Epub ahead of print]

Witzel I, Laakmann E, Weide R, Neunhöffer T, Park-Simon TJ, Schmidt M, Fasching PA, Hesse T, Polasik A, Mohrmann S, Würschmidt F, Schem C, Bechtner C, Würstlein R, Fehm T, Möbus V, Burchardi N, Loibl S, Müller V.
Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. Eur J Cancer. 2018;102:1-9.

Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J.
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31(11):2398-2406.

Tortorici MA, Lawo JP, Weide R, Jochems J, Puli S, Hofmann J, Pfruender D, Rojavin MA.
Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency. Int Immunopharmacol 2018; 66:119-126.

Chakupurakal G, Feiten S, Burkhard O, Reiser M, Ehscheidt P, Weide R.
Successful Evidence-Based Treatment of Patients with Advanced Pancreatic Cancer in Community-Based Oncology Group Practices Oncol Res Treat 2017;40:784-788

Kropff M, Vogel M, Bisping G, Schlag R, Weide R, Knauf W, Fiechtner H, Kojouharoff G, Kremers S, Berdel WE.
Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study Ann Hematol. 2017;96(11):1857-1866.

Weide R.
Versorgungsforschung in onkologischen Schwerpunktpraxen in Deutschland Der Onkologe 2017; 23:1-6

Weide R, Rendenbach B, Grundheber M, Burkhard O, Behringer J, Maasberg M, Ehscheidt P, Strehl JW, Hansen R, Feiten S.
Standard of care of patients with Chronic Myeloid Leukemia (CML) treated in community based oncology group practices between 2001-2015 in Rhineland-Palatinate (Germany) Applied Cancer Research 2017;37:26

Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H.
Immunoglobulin substitution in patients with indolent non-Hodgkin’s lymphoma. TumorDiagn u Ther 2016;37:393-397.

Feiten S, Dünnebacke J, Friesenhahn V, Heymanns J, Köppler H, Meister R, Thomalla J, van Roye C, Wey D, Weide R.
Follow-up Reality for Breast Cancer Patients – Standardised Survey of Patients and Physicians and Analysis of Treatment Data Geburtshilfe Frauenheilkd 2016; 76(05): 557-563

Feiten S, Weide R, Friesenhahn V, Heymanns J, Kleboth K, Köppler H, van Roye C, Thomalla J.
Adherence assessment of patients with metastatic solid tumors who are treated in an oncology group practice SpringerPlus (2016) 5:270

Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H.
Outpatient Management of Patients with Immune Thrombocytopenia (ITP) by Hematologists 1995-2014 Oncol Res Treat 2016;39:41-44.

Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H.
Immunoglobulin substitution in patients with indolent non-Hodgkin’s lymphoma. Dtsch Med Wochenschr 2015;140(19):e201-6.

Kurbacher CM, Fietz T, Diel I, Egert M, Hurtz H-J, Lück A, Weide R, Salat C, Wolff T, Zaiss M, Klare P, Losem C, Illmer T, Weißenborn G, Steffens C, Schulze M, Tesch H, Oskay-Oezcelik G, Teichmann B, Harde J, Scheuerlein RW.
NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim – First Interim Analysis. Oncol Res Treat 2015; 38: 221–229.

Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H.
Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors. SpringerPlus 2014 3:535.

Feiten S, Dünnebacke J, Heymanns J, Köppler H, Thomalla J, van Roye C, Wey D, Weide R.
Breast cancer morbidity – questionnaire survey of patients on the long term effects of disease and adjuvant therapy. Dtsch Arztebl Int 2014; 111: 537-44.

Herth I, Dietrich S, Benner A, Hegenbart U, Rieger M, Stadtherr P, Bondong A, Tran TH, Weide R, Hensel M, Knauf W, Franz-Werner J, Welslau M, Procaccianti M, Görner M, Meissner J, Luft T, Schönland S, Witzens-Harig M, Zenz T, Ho AD, Dreger.
The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison. Ann Oncol. 2014;25(1):200-6.

Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Köppler H, Mergenthaler U, Thomalla J, van Roye C, Weide R.
Psychosocial Distress in Caregivers of Patients with a Metastatic Solid Tumor in Routine Care: A Survey in a Community Based Oncology Group Practice in Germany. Cancer and Clinical Oncology 2013,2(2):1-10.

Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, Mergenthaler U, van Roye C, Köppler H.
Improved Survival of HER2-Positive Metastatic Breast Cancer in Routine Care Cancer and Clinical Oncology 2013,2(1):17-27

Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, van Roye C, Köppler H.
Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions. Leuk Lymphoma. 2013;54(8):1640-6.

Köppler H, Fuss H, Hurtz HJ, Knigge O, Losem C, Reschke D, Schmitz S, Weide R, Weiß J, Hallek M; GCLLSG.
Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG). Br J Haematol. 2012;158(2):238-41. 

Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Mergenthaler U, Thomalla J, van Roye C, Köppler H.
Identifying Caregivers and Their Meaning for Patients with Metastatic Solid Tumours in Routine Care: A Survey at a Community-Based Oncology Group Practice in Germany Cancer and Clinical Oncology 2012;1(1):41-51

Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P, Kelaidi C, Pfeilstöcker M, Nösslinger T, Sekeres M, Maciejewski J, Haase D, Schanz J, Seymour J, Kenealy M, Weide R, Lübbert M, Platzbecker U, Valent P, Götze K, Stauder R, Blum S, Kreuzer K-A, Schlenk R, Ganser A, Hofmann W-K, Aul C, Krieger O, Kündgen A, Haas R, Hasford J and Giagounidis A.
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study Leukemia 2012;26(6):1286-92.

Mergenthaler U, Heymanns J, Köppler H, Thomalla J, van Roye C, Schenk J, Weide R.
Evaluation of psychosocial distress in patients treated in a community-based oncology group practice in Germany Ann Oncol. 2011;22(4):931-8.

Weide R, Koeppler H, Antras L, Smith M, Chang MP, Green J, Wintfeld N, Neary MP, Duh MS.
Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review J Cancer Res Ther. 2010;6(1):31-5.

Köppler H, Heymanns J, Thomalla J, Kleboth K, Weide R.
The impact of new treatment options for advanced colorectal cancer on routine care: Results of a retrospective analysis of 206 consecutive patients treated in a community based oncology group practice Eur J Cancer Care (Engl.) 2010;19(6):795-802.

Schmitz S, Heymanns J.
Interdisziplinäre ambulante Versorgung
Der Onkologe 2009;15:1065-1069.

Weide R, Mergenthaler U, Friesenhahn V, Kleboth K, Heymanns J, Thomalla J, Köppler H.
Bendamustine/Mitoxantrone/Rituximab (BMR): A short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia (CLL)
Leuk. Lymphoma. 2009;50(9):1468-1474.

Rhiem K, Wappenschmidt B, Bosse K, Köppler H, Tutt AN, Schmutzler RK.
Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer.
Clin Oncol (R Coll Radiol). 2009; 21(6):448-50.

Diel IJ, Weide R, Köppler H, Antrás L, Smith M, Green J, Wintfeld N, Neary M, Duh MS.
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
Support Care Cancer. 2009; 17(6):719-25.

Steil S, Zerwas S, Moos G, Bittinger F, Hansen T, Mergenthaler U, Weide R.
CT-guided percutaneous core needle biopsy in oncology outpatients:sensitivity, specificity, complications.
Onkologie. 2009; 32(5):254-8.

Weide R, Mergenthaler U, Pandorf A, Arndt H, Heymanns J, Thomalla J, Köppler H.
Improved survival of patients with metastatic breast cancer in routine care: results of retrospective study in a community-based oncology group practice 1995-2005
Onkologie. 2009; 32(3):107-13.

Koeppler H, Heymanns J, Thomalla J, Kleboth K, Mergenthaler U, Weide R.
Treatment of Advanced Non Small Cell Lung Cancer in Routine Care: A Retrospective Analysis of 212 Consecutive Patients Treated in a Community Based Oncology Group Practice. Clinical Medicine: Oncology 2009: 3 63-70.

Schnittger S, Bacher U, Haferlach C, Beelen D, Bojko P, Bürkle D, Dengler R, Distelrath A, Eckart M, Eckert R, Fries S, Knoblich J, Köchling G, Laubenstein HP, Petrides P, Planker M, Pihusch R, Weide R, Kern W, Haferlach T.
Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis.
Haematologica. 2009; 94(1):141-4.

Weide R.
Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma.
Therapeutics and Clinical Risk Management 2008; 4(4):1-6.

Weide R, Arndt M, Pandorf A, Heymanns J, Thomalla J, Köppler H.
Ovarian Cancer Treatment Reality in Northern Rheinland-Pfalz (Germany). Suboptimal Surgical Treatment as the Cause for inferior survival. A Retrospective Study of 139 Consecutive Patients Receiving Chemotherapy and Palliative Care in an Oncology Group Practice.
Onkologie 2007; 30:611-617.

Weide R, Hess G, Köppler H, Heymanns J, Thomalla J, Aldaoud A, Losem C, Schmitz S, Haak U, Huber C, Unterhalt M, Hiddemann W, Dreyling M.
High Anti-Lymphoma Activity of Bendamustine/Mitoxantrone/Rituximab (BMR) in Rituximab Pretreated Relapsed or Refractory Indolent Lymphomas. A Multicenter Phase II Study of the German Low Grade Lymphoma Study Group (GLSG).
Leukemia and Lymphoma (2007), 48(7):1299-1306

Weide R, Heymanns J, Thomalla J, Köppler H.
Interaktiver Kleingruppenunterricht für Medizinstudenten der klinischen Semester in einer onkologischen Gemeinschaftspraxis.
GMS Z Med Ausbild (2007),24(1):Doc71